Skip to main content

Super navigation

  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home
Global websites
  • Global: English
Local websites
  • Germany: Deutsch
  • Japan: 日本語
  • Netherlands: Nederlands
  • Spain: Español
  • United Kingdom: English

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Press Releases

Press Releases

  • (-) Any
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
Reset

2021

May 7, 2021
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
April 28, 2021
argenx Management to Present at Upcoming Virtual Investor Conferences
March 30, 2021
argenx announces Annual General Meeting of Shareholders on May 11, 2021
March 4, 2021
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
March 2, 2021
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
February 25, 2021
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
February 5, 2021
argenx announces closing of global offering
February 4, 2021
argenx announces full exercise of underwriters’ option to purchase additional ADSs
February 2, 2021
argenx raises $1.0 billion in gross proceeds in a global offering
February 2, 2021
argenx Issues Statement Concerning Efgartigimod
February 1, 2021
argenx announces launch of proposed global offering
February 1, 2021
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Next page Next ›
  • Last page Last »
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2023 © argenx
Disclaimer
Privacy policy
Regulations